Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease

Gastroenterology
S SchreiberGerman ICAM-1 Study Group

Abstract

ISIS-2302, an antisense oligonucleotide directed against intercellular adhesion molecule 1, was effective in steroid refractory Crohn's disease in a pilot trial. The aim of this study was to investigate safety and efficacy of ISIS-2302 in chronic active Crohn's disease (CACD). A dose-interval, multicenter, placebo-controlled trial was conducted in 75 patients with steroid-refractory CACD (Crohn's Disease Activity Index [CDAI], 200-400). The primary endpoint was steroid-free remission (CDAI <150) at week 14. Only 2 of 60 (3.3%) ISIS-2302-treated and no placebo patients reached the primary endpoint. Steroid-free remission at week 26 (secondary endpoint) was reached in 8 of 60 (13.3%) active treatment and 1 of 15 (6.7%) placebo patients. A greater proportion of ISIS-2302-treated than placebo patients achieved a steroid dose <10 mg/day at weeks 14 and 26 (48.3% vs. 33.3% and 55.0% vs. 40.0%, respectively, and a glucocorticoid dose of 0 mg [prednisone equivalent] at week 26 [23.3% vs. 6.7%, respectively]). Treatment with ISIS-2302 was safe. The most common side effects were injection site reactions in the active treatment group (23% in ISIS-2302-treated patients vs. none in placebo patients). No statistically significant differences...Continue Reading

Citations

May 11, 2002·Critical Care Medicine·John M Harlan, Robert K Winn
Nov 21, 2002·Current Gastroenterology Reports·Geert D'Haens, Marco Daperno
Apr 23, 2004·Expert Opinion on Investigational Drugs·Radhika Srinivasan, Gary R Lichtenstein
Jan 12, 2005·Acta Clinica Belgica·F BaertP Rutgeerts
Jul 29, 2005·Immunological Reviews·Marko Salmi, Sirpa Jalkanen
Dec 2, 2005·Current Opinion in Gastroenterology·Wojciech Blonski, Gary R Lichtenstein
Jan 5, 2006·Autoimmunity·Erica Lee, Animesh A Sinha
Aug 29, 2006·World Journal of Gastroenterology : WJG·Kazuhiko NakamuraNaohiko Harada
Oct 24, 2006·Annals of the New York Academy of Sciences·Ossama A HatoumDavid G Binion
Jul 28, 2007·American Journal of Physiology. Gastrointestinal and Liver Physiology·Julián PanésPeter McLean
Apr 16, 2008·Expert Opinion on Therapeutic Targets·Arthur Kaser, Herbert Tilg
Jan 1, 2008·Gene Regulation and Systems Biology·Moizza Mansoor, Alirio J Melendez
Sep 1, 2006·Expert Review of Clinical Immunology·Jean Frédéric Colombel, Laurent Peyrin-Biroulet
Oct 14, 2009·Journal of Gastroenterology and Hepatology·Michael C Grimm
Apr 21, 2010·Expert Opinion on Emerging Drugs·Ulrike Strauch, Jürgen Schölmerich
Dec 30, 2011·Inflammopharmacology·Saskia Thomas, Daniel C Baumgart
Nov 25, 2011·The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi·Kyeong Ok Kim, Byung Ik Jang
Apr 21, 2012·American Journal of Physiology. Gastrointestinal and Liver Physiology·Qingjie Li, Sushil K Sarna
Feb 1, 2014·Alimentary Pharmacology & Therapeutics·T LobatónP Rutgeerts
Mar 19, 2015·The New England Journal of Medicine·Giovanni MonteleoneFrancesco Pallone
Apr 26, 2015·Drugs·Irene MarafiniGiovanni Monteleone
Feb 12, 2015·Clinical Pharmacology and Therapeutics·K O Arseneau, F Cominelli
Dec 28, 2018·International Immunology·Masayoshi OnukiKoji Hase
Dec 26, 2001·Current Opinion in Nephrology and Hypertension·Enyu Imai, Yoshitaka Isaka
May 10, 2003·Scandinavian Journal of Gastroenterology·B Vainer, O Haagen Nielsen
Feb 28, 2002·Expert Opinion on Investigational Drugs·Ece A MutluAli Keshavarzian
Nov 1, 2006·Journal of Gastroenterology and Hepatology·Qin OuyangShu-Dong Xiao
Jul 26, 2012·Clinical Pharmacology and Therapeutics·D A KatzkaM Camilleri
May 27, 2011·Journal of Medicinal Food·Aristea GioxariNikolaos K Andrikopoulos
May 8, 2014·Expert Review of Clinical Pharmacology·Svend T Rietdijk, Geert R D'Haens
Feb 12, 2013·Expert Opinion on Biological Therapy·Mahmoud H Mosli, Brian G Feagan
Mar 13, 2014·Der Internist·S Schreiber, O Bachmann
Nov 4, 2015·World Journal of Gastroenterology : WJG·Hidetoshi TakedatsuTakuji Torimura
Sep 13, 2014·Inflammatory Bowel Diseases·Irene MarafiniGiovanni Monteleone
Jul 4, 2017·Expert Opinion on Investigational Drugs·Vipul JairathBrian G Feagan
Oct 27, 2017·Immunotherapy·Thomas Greuter, Gerhard Rogler
Dec 25, 2017·Digestive Diseases and Sciences·Paolo GiuffridaAntonio Di Sabatino
Jun 1, 2004·Inflammatory Bowel Diseases·Severine Vermeire, Paul Rutgeerts
Feb 17, 2007·Inflammatory Bowel Diseases·Wojciech Blonski, Gary R Lichtenstein
Jun 6, 2003·Alimentary Pharmacology & Therapeutics·M Scribano, C Prantera
Sep 13, 2003·British Journal of Clinical Pharmacology·E Carty, D S Rampton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Related Papers

Inflammatory Bowel Diseases
Gert van Assche, Paul Rutgeerts
Current Opinion in Molecular Therapeutics
B YacyshynW Shanahan
Current Opinion in Investigational Drugs
A T Gewirtz, S Sitaraman
Documenta Ophthalmologica. Advances in Ophthalmology
A J LoteryA D Collins
© 2021 Meta ULC. All rights reserved